Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Musculoskeletal Symptoms Among Finnish Professional Orchestra Musicians.

Viljamaa K, Liira J, Kaakkola S, Savolainen A.

Med Probl Perform Art. 2017 Dec;32(4):195-200. doi: 10.21091/mppa.2017.4037.

PMID:
29231952
2.

ATPase-deficient mitochondrial inner membrane protein ATAD3A disturbs mitochondrial dynamics in dominant hereditary spastic paraplegia.

Cooper HM, Yang Y, Ylikallio E, Khairullin R, Woldegebriel R, Lin KL, Euro L, Palin E, Wolf A, Trokovic R, Isohanni P, Kaakkola S, Auranen M, Lönnqvist T, Wanrooij S, Tyynismaa H.

Hum Mol Genet. 2017 Apr 15;26(8):1432-1443. doi: 10.1093/hmg/ddx042.

3.

SNCA mutation p.Ala53Glu is derived from a common founder in the Finnish population.

Pasanen P, Palin E, Pohjolan-Pirhonen R, Pöyhönen M, Rinne JO, Päivärinta M, Martikainen MH, Kaasinen V, Hietala M, Gardberg M, Saukkonen AM, Eerola-Rautio J, Kaakkola S, Lyytinen J, Tienari PJ, Paetau A, Suomalainen A, Myllykangas L.

Neurobiol Aging. 2017 Feb;50:168.e5-168.e8. doi: 10.1016/j.neurobiolaging.2016.10.014. Epub 2016 Oct 19.

PMID:
27838048
4.

Linking Smoking, Coffee, Urate, and Parkinson's Disease - A Role for Gut Microbiota?

Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P.

J Parkinsons Dis. 2015;5(2):255-62. doi: 10.3233/JPD-150557. Review.

PMID:
25882059
5.

Gut microbiota are related to Parkinson's disease and clinical phenotype.

Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P.

Mov Disord. 2015 Mar;30(3):350-8. doi: 10.1002/mds.26069. Epub 2014 Dec 5.

PMID:
25476529
6.

Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology.

Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, Pöyhönen M, Paetau A.

Neurobiol Aging. 2014 Sep;35(9):2180.e1-5. doi: 10.1016/j.neurobiolaging.2014.03.024. Epub 2014 Mar 26.

PMID:
24746362
7.

[Nicotine and neurologic diseases--even a noxious substance may possess beneficial properties].

Kaakkola S, Tuominen R.

Duodecim. 2013;129(16):1654-60. Review. Finnish.

PMID:
24069634
8.

Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.

Kaakkola S.

Int Rev Neurobiol. 2010;95:207-25. doi: 10.1016/B978-0-12-381326-8.00009-0. Review.

PMID:
21095464
9.

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

Kuoppamäki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, Hänninen J, Löyttyniemi E, Kailajärvi M, Ruokoniemi P, Ellmén J.

Eur J Clin Pharmacol. 2009 May;65(5):443-55. doi: 10.1007/s00228-009-0622-y. Epub 2009 Feb 20.

PMID:
19229530
10.

Vapina.

Kaakkola S.

Duodecim. 2007;123(18):2189. Finnish. No abstract available.

PMID:
18020275
11.

Parkinsonin tauti.

Marttila R, Heikkinen E, Hänninen J, Jousilahti P, Jäättelä A, Kaakkola S, Keränen T, Sotaniemi K, Teräväinen H.

Duodecim. 2006;122(21):2655-6. Finnish. No abstract available.

PMID:
17233345
12.

Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).

Myllylä V, Haapaniemi T, Kaakkola S, Kinnunen E, Hartikainen P, Nuutinen J, Rissanen A, Kuopio AM, Jolma T, Satomaa O, Heikkinen H.

Acta Neurol Scand. 2006 Sep;114(3):181-6.

PMID:
16911346
13.

How useful is [123I]beta-CIT SPECT in clinical practice?

Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J.

J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1211-6.

14.

Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin.

Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, Rantamaki M, Goethem GV, Lofgren A, Hackman P, Paetau A, Kaakkola S, Majamaa K, Varilo T, Udd B, Kaariainen H, Bindoff LA, Suomalainen A.

Am J Hum Genet. 2005 Sep;77(3):430-41. Epub 2005 Jul 27.

15.

The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats.

Janhunen S, Mielikäinen P, Paldánius P, Tuominen RK, Ahtee L, Kaakkola S.

Naunyn Schmiedebergs Arch Pharmacol. 2005 Jun;371(6):480-91. Epub 2005 Jul 13.

PMID:
16012872
16.

Cholinergic modulation of preattentive auditory processing in aging.

Pekkonen E, Jääskeläinen IP, Kaakkola S, Ahveninen J.

Neuroimage. 2005 Aug 15;27(2):387-92.

PMID:
15921933
17.

[Will the mystery of Parkinson's disease be resolved?].

Lyytinen J, Kaakkola S.

Duodecim. 2005;121(3):275-84. Review. Finnish. No abstract available.

PMID:
15787285
18.

De novo paracentric inversion 14q13q24.1 in a patient with severe involuntary movements, epilepsy, oligodontia and dysmorphic features.

Peippo M, Tengström C, Arvio M, Valanne L, Oksanen V, Kaakkola S, Ignatius J.

Genet Couns. 2004;15(3):341-6.

PMID:
15517827
19.

POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement.

Van Goethem G, Luoma P, Rantamäki M, Al Memar A, Kaakkola S, Hackman P, Krahe R, Löfgren A, Martin JJ, De Jonghe P, Suomalainen A, Udd B, Van Broeckhoven C.

Neurology. 2004 Oct 12;63(7):1251-7.

PMID:
15477547
20.

Clinical advantages of COMT inhibition with entacapone - a review.

Gordin A, Kaakkola S, Teräväinen H.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1343-63. Epub 2004 Aug 3. Review.

PMID:
15340869
21.

The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.

Lyytinen J, Kaakkola S, Gordin A, Kultalahti ER, Teräväinen H, Sovijärvi A.

Parkinsonism Relat Disord. 2002 Jun;8(5):349-55.

PMID:
15177064
22.

Effects of an acute D2-dopaminergic blockade on the somatosensory cortical responses in healthy humans: evidence from evoked magnetic fields.

Huttunen J, Kähkönen S, Kaakkola S, Ahveninen J, Pekkonen E.

Neuroreport. 2003 Aug 26;14(12):1609-12.

PMID:
14502085
23.

Effects of scopolamine on MEG spectral power and coherence in elderly subjects.

Osipova D, Ahveninen J, Kaakkola S, Jääskeläinen IP, Huttunen J, Pekkonen E.

Clin Neurophysiol. 2003 Oct;114(10):1902-7.

PMID:
14499752
24.

Economic burden and quality of life impairment increase with severity of PD.

Keränen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, Kola H, Ylikoski A, Satomaa O, Kovanen J, Taimela E, Haapaniemi H, Turunen H, Takala A.

Parkinsonism Relat Disord. 2003 Jan;9(3):163-8.

PMID:
12573872
25.

Dopamine modulates involuntary attention shifting and reorienting: an electromagnetic study.

Kähkönen S, Ahveninen J, Pekkonen E, Kaakkola S, Huttunen J, Ilmoniemi RJ, Jääskeläinen IP.

Clin Neurophysiol. 2002 Dec;113(12):1894-902.

PMID:
12464326
26.

Position of COMT inhibition in the treatment of Parkinson's disease.

Gordin A, Kaakkola S, Teräväinen H.

Adv Neurol. 2003;91:237-50. Review. No abstract available.

PMID:
12442682
27.

Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K.

Br J Clin Pharmacol. 2002 Oct;54(4):363-71.

28.

[Neurological problems in a musician].

Kaakkola S, Larsen A.

Duodecim. 2002;118(15):1603-7. Review. Finnish. No abstract available.

PMID:
12244637
29.

[Diagnostics and treatment of botulism].

Kaakkola S.

Duodecim. 2001;117(4):421-5; quiz 425, 441. Finnish. No abstract available.

PMID:
12092386
30.

Memory-based comparison process not attenuated by haloperidol: a combined MEG and EEG study.

Pekkone E, Hirvonen J, Ahveninen J, Kähkönen S, Kaakkola S, Huttunen J, Jääskeläinen IP.

Neuroreport. 2002 Jan 21;13(1):177-81.

PMID:
11924884
31.

Defective cortical drive to muscle in Parkinson's disease and its improvement with levodopa.

Salenius S, Avikainen S, Kaakkola S, Hari R, Brown P.

Brain. 2002 Mar;125(Pt 3):491-500.

PMID:
11872607
32.

Aging and cholinergic modulation of the transient magnetic 40-Hz auditory response.

Ahveninen J, Jääskeläinen IP, Kaakkola S, Tiitinen H, Pekkonen E.

Neuroimage. 2002 Jan;15(1):153-8.

PMID:
11771983
33.

Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study.

Kähkönen S, Ahveninen J, Jääskeläinen IP, Kaakkola S, Näätänen R, Huttunen J, Pekkonen E.

Neuropsychopharmacology. 2001 Oct;25(4):498-504.

34.

No evidence for dependence of early cortical auditory processing on dopamine D(2)-receptor modulation: a whole-head magnetoencephalographic study.

Kähkönen S, Ahveninen J, Pekkonen E, Kaakkola S, Huttunen J, Peltonen T, Ilmoniemi RJ, Jääskeläinen IP.

Psychiatry Res. 2001 Aug 25;107(2):117-23.

PMID:
11530277
35.

Auditory sensory memory and the cholinergic system: implications for Alzheimer's disease.

Pekkonen E, Hirvonen J, Jääskeläinen IP, Kaakkola S, Huttunen J.

Neuroimage. 2001 Aug;14(2):376-82.

PMID:
11467911
36.

The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.

Lyytinen J, Sovijärvi A, Kaakkola S, Gordin A, Teräväinen H.

Clin Neuropharmacol. 2001 Jan-Feb;24(1):50-7.

PMID:
11290882
37.

Scopolamine reduces the P35m and P60m deflections of the human somatosensory evoked magnetic fields.

Huttunen J, Jääskeläinen IP, Hirvonen J, Kaakkola S, Ilmoniemi RJ, Pekkonen E.

Neuroreport. 2001 Mar 5;12(3):619-23.

PMID:
11234776
38.

Suppression of transient 40-Hz auditory response by haloperidol suggests modulation of human selective attention by dopamine D2 receptors.

Ahveninen J, Kähkönen S, Tiitinen H, Pekkonen E, Huttunen J, Kaakkola S, Ilmoniemi RJ, Jääskeläinen IP.

Neurosci Lett. 2000 Sep 29;292(1):29-32.

PMID:
10996442
39.

Clinical and genetic findings in Finnish ataxia patients with the spinocerebellar ataxia 8 repeat expansion.

Juvonen V, Hietala M, Päivärinta M, Rantamäki M, Hakamies L, Kaakkola S, Vierimaa O, Penttinen M, Savontaus ML.

Ann Neurol. 2000 Sep;48(3):354-61.

PMID:
10976642
40.

Entacapone and selegiline with L-dopa in patients with Parkinson's disease: an interaction study.

Lyytinen J, Kaakkola S, Gordin A, Kultalahti E, Teräväinen H.

Parkinsonism Relat Disord. 2000 Oct 1;6(4):215-222.

PMID:
10900396
41.
42.

Scopolamine augments transient auditory 40-hz magnetic response in humans.

Ahveninen J, Tiitinen H, Hirvonen J, Pekkonen E, Huttunen J, Kaakkola S, Jääskeläinen IP.

Neurosci Lett. 1999 Dec 24;277(2):115-8.

PMID:
10624823
43.

Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Männistö PT, Kaakkola S.

Pharmacol Rev. 1999 Dec;51(4):593-628. Review. No abstract available.

PMID:
10581325
44.

Scopolamine enhances middle-latency auditory evoked magnetic fields.

Jääskeläinen IP, Hirvonen J, Huttunen J, Kaakkola S, Pekkonen E.

Neurosci Lett. 1999 Jan 4;259(1):41-4.

PMID:
10027551
45.

A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.

Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H.

J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):6-12.

46.

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.

Mov Disord. 1997 Jul;12(4):497-505.

PMID:
9251066
47.

[Ataxias and their differential diagnostics].

Kaakkola S, Rinne R.

Duodecim. 1997;113(18):1773-82. Review. Finnish. No abstract available.

PMID:
10892069
48.

Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease.

Kaakkola S, Teräväinen H, Ahtila S, Karlsson M, Naukkarinen T, Rita H, Gordin A.

Eur J Neurol. 1995 Sep;2(4):341-7. doi: 10.1111/j.1468-1331.1995.tb00137.x.

PMID:
24283686
49.

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.

Ahtila S, Kaakkola S, Gordin A, Korpela K, Heinävaara S, Karlsson M, Wikberg T, Tuomainen P, Männistö PT.

Clin Neuropharmacol. 1995 Feb;18(1):46-57.

PMID:
8665534
50.

Diagnosis and clinical characteristics of ocular Lyme borreliosis.

Karma A, Seppälä I, Mikkilä H, Kaakkola S, Viljanen M, Tarkkanen A.

Am J Ophthalmol. 1995 Feb;119(2):127-35.

PMID:
7832219

Supplemental Content

Loading ...
Support Center